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Summary
Objective: The present study aimed to investigate the modulation of membrane-bound intercellular adhesion molecule-1 (mICAM-1) and
soluble ICAM-1 (sICAM-1) expression by tumor necrosis factor-alpha (TNFa) in human osteoarthritic (OA) osteoblasts.
Methods: Cultured human primary osteoblasts were stimulated with increasing concentrations of human recombinant TNFa. Expression of
mICAM-1 and sICAM-1 was evaluated by immunocytochemistry, enzyme-linked immunosorbent assay and semi-quantitative reverse tran-
scriptase-polymerase chain reaction. In addition, we investigated the molecular mechanisms underlying ICAM-1 induction by TNFa, focusing
on the activation of the mitogen-activated protein kinases (MAPKs) and nuclear factor-kappaB (NF-kB) pathways.
Results: Our data showed that TNFa dose-dependently increased mICAM-1 and sICAM-1 expression at the protein and mRNA levels in OA
osteoblasts. The inhibitor of de novo mRNA synthesis, actinomycin D, suppressed TNFa-induced mICAM-1 and sICAM-1 expression. Upon
examination of the signaling components, we found that TNFa was a potent activator of p38, p44/42, p54/46 MAPK, and IkappaBalpha (IkBa).
The chemical inhibitors of p38, p44/42 MAPK, and NF-kB blocked TNFa-induced mICAM-1 expression but not that of sICAM-1. Transfection
experiments revealed that p38 MAPK or IkappaB kinase alpha (IKKa) overexpression enhanced TNFa-induced mICAM-1 production. Fur-
thermore, osteoblasts treatment with a chemical inhibitor of metalloproteinase-9 (MMP-9) activity, a proteolytic enzyme involved in ICAM-1
cleavage, evoked a signiﬁcant 25% decrease of TNFa-induced sICAM-1 release.
Conclusion: Taken together, these ﬁndings illustrate the central role played by TNFa in the regulation of ICAM-1. We suggest that TNFa dif-
ferentially regulates sICAM-1 and mICAM-1 expression and that sICAM-1 release involves, in part, the proteolytic cleavage of mICAM-1 by
MMP-9. The capacity of the MMP-9 inhibitor to prevent sICAM-1 production may be useful for the development of novel therapeutic ap-
proaches relevant to OA.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a disease characterized by progres-
sive degradation of articular cartilage accompanied by sec-
ondary inﬂammation of the synovial membranes and
abnormal subchondral trabecular bone remodeling1,2. Sev-
eral lines of evidence indicate that patients with OA exhibit
high bone turnover involving both bone formation and re-
sorption. Increased bone resorption followed by elevated
bone and osteophyte formation have also been observed
in experimental models of OA3,4. It is believed that alter-
ations in osteoblast metabolism play an important role in os-
teoclast maturation and activation by producing excess
bone-resorbing cytokines and other pro-inﬂammatory medi-
ators5. Such factors include urokinase plasminogen activa-
tor (uPA), insulin growth factor-1 (IGF-1) and prostaglandin
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6e8. In early experimental dog model of OA, Pel-
letier et al. showed a signiﬁcant loss of subchondral bone
associated with the development of OA cartilage lesions
and with an increased osteoclast population that stained
strongly positive for cathepsin K and metalloproteinase-13
(MMP-13)3. The use of a cyclooxygenase-2 (COX-2) inhib-
itor, licofelone, or bone resorption inhibitors, calcitonin or
alendronate, suppressed bone resorption and prevented
the subsequent increment of bone formation mainly through
the inhibition of osteoclast activities4,9.
Adhesion molecules, such as integrins, and the immuno-
globulin (Ig) superfamily of intercellular and vascular adhe-
sion molecules (ICAM-1 and VCAM-1) play major roles in
cellecell and celleextracellular matrix interactions10. Of
these, ICAM-1 binds to its counter receptor leukocyte func-
tion-asssociated-1 molecule (LFA-1 or CD11a/CD18) as
well as Mac-1 (CR3 or CD11a/CD18) on neutrophils, T-cells
and macrophages10e12, providing a mechanism for the
selective recruitment of leukocytes in different pathologic
situations13. Many cytokines, such as interferon-gamma
(IFN-g), interleukin-1 beta (IL-1b) and tumor necrosis fac-
tor-alpha (TNFa), induce ICAM-1 expression on the surface
of synoviocytes14, keratocytes15, and human airway00
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also detected in the serum of normal individuals, and ele-
vated levels are found during various pathological condi-
tions, including inﬂammatory, immune and malignant
diseases17e19. However, the role of sICAM-1 and its
mode of production remain elusive. Controversy still sur-
rounds the exact origin of sICAM-1. In some cell types,
proteolytic cleavage from membrane-bound ICAM-1
(mICAM-1) has been proposed as a mechanism for the
generation of sICAM-1, and its presence would therefore
reﬂect membrane expression of the protein20,21. On the
other hand, some researchers have identiﬁed a speciﬁc
mRNA coding for sICAM-1 in cells, suggesting that at least
two modes of sICAM-1 production exist22,23.
In bone metabolism, ICAM-1 exerts important osteotropic
effects by mediating cellecell adhesion of osteoblasts and
osteoclast precursors, thereby facilitating osteoclast differ-
entiation and bone resorption24,25. Furthermore, it has
been shown that osteoblasts adhere to opposing cells
through ICAM-1, VCAM-1 and LFA-3, resulting in the acti-
vation of intracellular signals and leading to the production
of bone-resorbing cytokines, such as TNFa, IL-1b and
IL-6. Interestingly, ICAM-1 expression and sICAM-1 release
from cells are increased by these cytokines, which are
found to be major contributors to bone diseases26e28.
Abnormal sICAM-1 levels in bone diseases have been re-
ported solely in rheumatoid arthritis so far, but no direct
role has been attributed in the pathogenesis of this disease.
Our group has demonstrated the induction of intracellular
signaling in pre-osteoclast cells after incubation with sI-
CAM-1 (study in progress), indicating a possible active
role for sICAM-1 in osteoclast-dependent diseases. Al-
though widely reported in other cell types, less attention
has been paid to the regulation of mICAM-1 expression
and sICAM-1 production in osteoblasts14e16.
Therefore, the aim of this study was to demonstrate the
effect of the bone-resorbing cytokine TNFa on mICAM-1
and sICAM-1 expression in human osteoblasts isolated
from OA patients. We also wanted to examine whether sI-
CAM-1 is cleaved from the membrane of osteoblasts by
a proteolytic cleavage mechanism. We believe that clarify-
ing the modulation and production of mICAM-1 and sI-
CAM-1 in the bone environment could lead to a better
understanding of their respective roles in bone pathology.
Materials and methods
IN VITRO OSTEOBLAST CULTURE
Trabecular bone specimens were collected from patients
suffering from advanced OA and undergoing primary total
knee replacement (n¼ 36). The diagnosis was established
according to American College of Rheumatology criteria29.
The experimental protocol was approved by the Research
Ethics Board at Sacre-Cœur Hospital. Bone specimens
were taken within 5 mm of the subchondral bone plate. Ev-
ery specimen was harvested from the most damaged por-
tion of the tibial plateau. Osteoblast cultures were
prepared as already described5.
Brieﬂy, trabecular bone samples were cut into small
pieces of 2 mm3 prior to their sequential digestion in the
presence of 1 mg/ml collagenase type I (SigmaeAldrich,
Oakville, ON, Canada) in BGJb media (Invitrogen Life Tech-
nologies, Burlington, ON, Canada) without serum at 37C
for 30, 30, and 240 min. After being washed with the same
media, the digested bone pieces were cultured in 25 cm2
plastic cell culture ﬂasks (Corning Incorporated - LifeSciences, Acton, MA, USA) with BGJb medium containing
20% fetal bovine serum (FBS) (Invitrogen Life Technolo-
gies). This medium was replaced every 2 days until cell out-
growths appeared around the explants. It was demonstrated
that cells obtained under these culture conditions had an os-
teoblast-like cell phenotype30e32. At conﬂuency, the cells
were split once and plated at 50,000 cells/cm2 in culture
plates (Falcon, Lincoln Park, NJ, USA) with Ham’s F12/Dul-
becco’s modiﬁed Eagle medium (HAMF12/DMEM; Sig-
maeAldrich) containing 10% FBS plus 50 mg/ml ascorbic
acid, and grown to conﬂuence again. Only ﬁrst-passage
cells were used in our experiments.
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
First-passage trabecular osteoblasts were incubated in
0.5% FBS/HAMF12/DMEM for 48 h with increasing concen-
trations of TNFa (0e10 ng/ml). After incubation, the culture
medium was collected, and sICAM-1 level was quantiﬁed
with a speciﬁc commercial kit from R&D Systems (Minneap-
olis, MN, USA), according to the manufacturer’s instruc-
tions. The sensitivity of the assays was 3 pg/ml. Each
ELISA was performed in duplicate according to the manu-
facturer’s speciﬁcations. Protein level in the cell lysates
was measured by the bicinchoninic acid method33.
IMMUNOCYTOCHEMICAL STAINING
Cellular surface ICAM-1 expression was analyzed by im-
munocytochemical staining34. Osteoblasts (5 103) were
transferred to eight-well culture chamber slides (Lab-Tek,
Nalge Nunc International, Naperville, IL, USA), and incu-
bated for 16 h without or with 1 ng/ml TNFa (R&D Systems).
Afterwards, the cells were washed twice with phosphate
buffered salin (PBS) and ﬁxed for 15 min at room tempera-
ture with PBS containing 10% formaldehyde (Tissuﬁx, Lab-
oratoire Gilles Chaput Inc., Montreal, QC, Canada). After
washing three times with PBS, the cells were incubated
for 30 min in a DAKO antibody diluent buffer containing
mouse monoclonal anti-ICAM-1 antibody (DAKO, Carpinte-
ria, CA, USA). In our experiments, we have used different
dilution of the anti-mICAM antibody 1:100, 1:500, 1:1000,
and 1:10,000. The optimal dilution of the antibody obtained
in our experiments was 1:1000. Then, cells were washed
with 0.05% TweenePBS and incubated for 10 min with
goat anti-mouse IgGehorseradish peroxidase (HRP) conju-
gate (DAKO Envision System). Color was developed with
3,30-diaminobenizidine (DAKO Liquid DAB) containing hy-
drogen peroxide, and the slides were examined under a light
microscope (Leitz Orthoplan, Wild Leitz, Ville St-Laurent,
QC, Canada). The numbers of total and coloured osteo-
blasts were counted separately, at 400 magniﬁcation,
from three ﬁelds of each well. The results were expressed
as the percentage of coloured osteoblasts34.
SEMI-QUANTITATIVE REVERSE TRANSCRIPTASE-
POLYMERASE CHAIN REACTION (RT-PCR)
Total RNA was extracted from the treated or un-treated
osteoblasts using TRIzol reagent (Invitrogen Life Technolo-
gies), according to the manufacturer’s instructions. RT-PCR
was performed in a Thermocycler (Waterman, Biometra
GmbH, Go¨ttingen, Germany) with 1 mg of total RNA. These
assays were undertaken with enzymes and reagents of the
SuperScript one-step RT-PCR kit manufactured by Invitro-
gen Life Technologies. Each RT-PCR consisted of cDNA
synthesis for 30 min at 42C and denaturation for 5 min at
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naturation step of 45 s at 95C and an annealing/elongation
step of 60 s at 55C. For the last cycle, the elongation step
was prolonged to 10 min at 72C. Primers for the detection
of mICAM-1 and sICAM-1 were based on those described
previously by Wakatsuki et al.23. The sequences of the for-
ward primer used to detect mICAM-1 and sICAM-1 were:
50-CAA GGG GAG GTC ACC CGC GAG GTG-30 and 50-CAA
GGG AGG TCA CCC GCG AGC C-30. Both primers were
combined with a common reverse primer having the follow-
ing sequence: 50-TGC AGT GCC CAT TAT GAC TG-30. The
sequences for GADPH, which served as a positive control,
were 50-CCACCCATGGCAAATCCATGGCA-30 (forward)
and 50-TCTAGACGGCAGGTCAQGGTCCAQCC-30 (re-
verse) (BioCorp Inc., Montreal, QC, Canada).
RT-PCR products were separated on 2% agarose gel
and stained with ethidium bromide solution (10 ng/ml).
Semi-quantitative measurements were made by taking den-
sity readings of each band in a digital imaging system
(G-image 2000, Canberra Packard Canada, Mississauga,
ON, Canada). cDNA relative units for ICAM-1 were normal-
ized to that of glyceraldehyde-6-phosphate dehydrogenase
(GAPDH). The data were expressed as percentages of the
non-treated control value35.
WESTERN BLOTTING
Brieﬂy, 20 mg of cellular protein extract were subjected to
10% sodium dodecyl sulfate-polyacrylamide gel electropho-
resis under reducing conditions and transferred onto nitro-
cellulose membrane (Bio-Rad, Hercules, CA, USA). The
membranes were immersed for 3 h in a blocking solution
consisting of TTBS (Tris 20 mM, pH 7.4, NaCl 137 mM,
0.1% Tween 20) and 5% skim milk, and washed twice
with TTBS for 15 min. They were then incubated overnight
in TTBS containing 0.25% skim milk, polyclonal rabbit
anti-phospho-p38, anti-phospho-p44/42, anti-phospho-p54/
46 mitogen-activated protein kinase (MAPK), anti-phos-
pho-IkappaBalpha (IkBa) (1:1000, Cell Signaling Technol-
ogy, Beverly, MA, USA), or anti-MMP-9 (1:1000,
Calbiochem, San Diego, CA, USA). The membranes were
washed three times with TTBS, and incubated for 1 h at
22C with the second antibody anti-rabbit IgGeHRP
(1:1000, Cell Signaling Technology), then washed again.
Immunoreactive proteins were visualized with LumiGLO
Chemiluminesent substrate (Cell Signaling Technology).
The membranes were prepared for autoradiography and
exposed to Kodak X-Omat ﬁlm (Eastman Kodak Ltd.,
Rochester, NY, USA).
PROTEIN KINASES, NUCLEAR FACTOR-KAPPAB (NF-kB),
AND MMP-9 INHIBITION
Osteoblasts were pre-incubated for 60 min with actinomy-
cin D (ActD) (RNA polymerase II inhibitor), MAPK inhibitors
(PD98059 and SB202190), NF-kB inhibitor (PDTC), or
MMP-9 inhibitor I (Calbiochem) before the addition of
10 ng/ml TNFa for 24 h at 37C. After incubation, mICAM-
1 and sICAM-1 expressions were measured by immunocy-
tochemical staining and ELISA as described above.
PLASMIDS AND TRANSIENT TRANSFECTIONS
The expression vectors for wild type (WT) pCMV-Flag-
p38 and dominant negative (DN) pCMV-Flag-p38 MAPK
were kind gifts from Dr R.J. Davis (University ofMassachusetts). The expression vector for IkappaB kinase
alpha (IKKa) was generously donated by Dr M. Karin (Uni-
versity of California, San Diego, La Jolla, CA). Brieﬂy, hu-
man MG-63 osteoblast-like line cells (ATCC, Rockville,
MD, USA) (around 50% conﬂuence) were transiently trans-
fected with vectors of WT or DN p38 MAPK, or IKKa fol-
lowed by stimulation with TNFa (10 ng/ml) in 12-well
cluster plates using lipofectamine 2000 reagents (Invitro-
gen Life Technologies) according to the manufacturer’s pro-
tocol. Twenty-four hours after transfection, the culture
medium was collected and mICAM-1 expression levels
were quantiﬁed by ELISA as described by Yang et al.
with some modiﬁcations36. Brieﬂy, the cells were washed
twice with PBS and ﬁxed at room temperature with 1%
(w/v) paraformaldehyde/glutaraldehyde for 30 min. After
washing with PBS, they were blocked with PBS containing
5% (w/v) bovine serum albumin and 0.05% (v/v) Tween 20
for 15 min before being incubated with monoclonal anti-
ICAM-1 antibody (1:100) for 1 h and then with HRP-labeled
anti-mouse antibody (1:1000) for 30 min. After each incuba-
tion, the cells were washed twice with PBS. Tetramethyl-
benzidine substrate (SigmaeAldrich) was then applied to
them for 30 min, after which 1 M H2SO4 acid was added
to stop the reaction. Absorbance was measured at 450 nm.
STATISTICAL ANALYSIS
The results are expressed as means S.E.M.. All assays
were performed in duplicate. Statistical signiﬁcance was as-
sessed by Student’s t test, and P< 0.05 was considered
signiﬁcant.
Results
We ﬁrst examined the presence of TNFa levels in osteo-
blast cultures to be certain that endogenous production
would not inﬂuence ICAM-1 expression. TNFa could not
be detected in the cell culture supernatant, even with
a high-sensitivity ELISA kit (data not shown). However,
the addition of increasing concentrations of TNFa to osteo-
blasts signiﬁcantly enhanced mICAM-1 and sICAM-1 pro-
duction [Fig. 1(A and B)]. These results were conﬁrmed at
the mRNA level in OA osteoblasts where, again, dose-
dependent increases of mICAM-1 and sICAM-1 were ob-
served after TNFa stimulation, correlating with the protein
expression pattern [Fig. 1(C)].
Immunostaining of osteoblasts with ICAM-1 antibody re-
vealed that this protein was expressed at basal levels in un-
stimulated cells with a mean S.E.M. of 29 6% (n¼ 3
experiments) [Fig. 2(A)]. In the presence of 1 ng/ml TNFa
(16 h of incubation), the percentage of positively-stained os-
teoblasts increased signiﬁcantly with a mean S.E.M. of
87 9% (n¼ 3 experiments) [Fig. 2(B)]. Staining speciﬁcity
was conﬁrmed by substitution of the primary mICAM-1 anti-
body with an autologous preimmune serum [Fig. 2(C)]. In-
cubation of osteoblasts with 1 ng/ml TNFa for different
incubation periods revealed that the effect on mICAM-1
surface expression was time-dependent as heightened
surface expression was apparent as early as 4 h after ex-
posure to TNFa, with a maximal effect at 16 h (results not
shown).
Next, we demonstrated that TNFa increased mICAM-1
and sICAM-1 mRNA levels required de novomRNA synthe-
sis, by pre-incubating osteoblasts with ActD before adding
10 ng/ml TNFa (Fig. 3). The expression of both mICAM-1
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Fig. 1. (A) Effects of TNFa on mICAM-1 expression. OA osteoblasts
were incubated for 18 h in the absence or presence of the indicated
concentrations of TNFa (n¼ 6). Then, mICAM-1 expression was
evaluated by immunocytochemical staining using a speciﬁc anti-
mICAM-1 antibody. Data are expressed as the percentage of positive
osteoblasts and are means S.E.M.. (B) Effects of TNFa on sICAM-1
release. OA osteoblasts (n ¼ 3) were incubated for 48 h in the
absence or presence of the indicated concentrations of TNFa.
Then, sICAM-1 production was evaluated by ELISA. The data were
expressedaspg/mgproteinandaremeans S.E.M.. (C)Representative[Fig. 3(A and B)] and sICAM-1 [Fig. 3(C and D)] at the
mRNA and protein levels was completely blocked by the
RNA synthesis inhibitor ActD.
To gain insight into the signaling pathways activated by
TNFa in human OA osteoblasts, we ﬁrst examined the
TNFa-induced phosphorylation patterns of MAPKs and
NF-kB over increasing periods of time. Our data indicated
that TNFa stimulated p38, p42/p44, and p54/46 MAPK as
well as IkBa phosphorylation within 5 min (Fig. 4). p38
MAPK remained in a phosphorylated state for w60 min of
incubation, but p44/42, p54/46 MAPK and IkBa activation
peaked at 15 min, and decreased thereafter at 60 min. No
change in the total protein level of MAPKs was noted
(data not shown).
To better deﬁne the TNFa signaling cascades involved in
ICAM-1 synthesis, OA osteoblasts were pre-incubated with
chemical inhibitors of p38 MAPK (SB202190), p44/42
(PD98059), and NF-kB (PDTC) before adding 10 ng/ml
TNFa. mICAM-1 protein expression was reduced with
SB202190 [Fig. 5(A)], PD98059 [Fig. 5(B)], and PDTC
[Fig. 5(C)]. In contrast, TNFa-induced sICAM-1 release
was not affected by any of the chemical inhibitors.
To clarify the role of p38 MAPK and IKKa in TNFa-medi-
ating mICAM-1 production, we conducted transfection ex-
periments with WT and DN vectors of p38 MAPK or IKKa
after TNFa treatment. Overexpression of WT p38 MAPK
or IKKa plasmids markedly increased basal mICAM-1 pro-
tein expression, and TNFa treatment further enhanced
mICAM-1 expression compared to TNFa alone (Fig. 6).
However, overexpression of DN p38 MAPK abrogated this
effect (data not shown).
Finally, to get a better understanding of MMP-mediating
mICAM-1 cleavage, we used MMP-9 inhibitor I to evaluate
other possible mechanisms involved in sICAM-1 produc-
tion. We observed that the addition of MMP-9 inhibitor
I (10 nM) signiﬁcantly reduced 25% of TNFa-enhanced
sICAM-1 release and did not change basal sICAM-1
production [Fig. 7(A)]. To conﬁrm the ability of TNFa to in-
duce MMP-9 synthesis, OA osteoblasts were treated with
working concentrations of this cytokine (0.1e10 ng/ml),
and MMP-9 was measured in the culture media. Western
blotting analysis revealed that TNFa dose-dependently in-
creased MMP-9 release by osteoblasts [Fig. 7(B)].
Discussion
ICAM-1 has previously been reported to be involved in
osteoclast differentiation and bone resorption. In a co-cul-
ture system of mouse spleen cells and osteoblasts or stro-
mal cells, cellular interaction through ICAM-1 could be
blocked by anti-CD54 monoclonal antibodies, which re-
sulted in decreased osteoclast formation in vitro24,25. Fur-
ther, a previous study by our group showed that ICAM-1
semi-quantitative RT-PCR gel for ICAM-1 mRNA analysis. The cells
were incubated for 1 h in the absence or presence of the indicated
concentrations of TNFa. The experiment was completed with 1 mg
RNA for each test and 35 cycles of PCR for ICAM-1 and 25 cycles
of PCR for the internal positive control, GADPH. The gel is represen-
tative of three independent experiments. mRNA levels (arbitrary
units) were then quantiﬁed by densitometry. mICAM-1 and sICAM-
1 levels were normalized against those of GAPDH mRNA and ex-
pressed as a percentage of untreated cells. Statistical analysis was
performed by Student’s t test. P values are compared to the corres-
ponding value for cells incubated in the absence of TNFa. *P< 0.05,
**P< 0.01, ***P< 0.001.
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Fig. 2. Representative immunocytochemical staining of mICAM-1 expression. Osteoblasts were incubated for 16 h in the absence (A) or pres-
ence of TNFa at 1 ng/ml (B). Then, cell surface ICAM-1 expression was evaluated by immunocytochemical staining with antibodies speciﬁc for
this protein, or substitution of primary antibody mICAM-1 with autologous preimmune serum as a control of staining speciﬁcity (C). mICAM-1-
positive cells were detected with diaminobenzidine, and nuclei were counterstained with Hematoxylin (see Materials and methods, original
magniﬁcation 400). Immunocytochemistry data represent three independent experiments.expression on human osteoblasts obtained from OA or os-
teoporotic patients was higher when compared to normal
human osteoblasts. Also, IL-6 and PGE2 levels in superna-
tant were found to be elevated with high ICAM-1 expres-
sion34. Several studies have demonstrated increased
bone remodeling and osteoclast activity in OA3. Biphosph-
onates, drugs known to inhibit osteoclasts, and licofelone,
a COX inhibitor capable of lowering IL-6 and PGE2 levels,
have been seen to reduce osteoclast activity in the setting
of OA3,4. Because of the role of ICAM-1 in osteoclast re-
cruitment, its differential expression in diseases such as
OA, and the increased osteoclast activity observed in OA,the understanding of the modulation of ICAM-1 expression
and the mechanisms regulating it in OA bone could offer
new potential therapeutic targets in OA.
So far, no study has looked at the expression and intra-
cellular signaling of mICAM-1 and sICAM-1 in human oste-
oblasts. As demonstrated in our investigation, stimulation of
osteoblasts with TNFa increased mICAM-1 and sICAM-1
expression at the protein and mRNA levels. It is noteworthy
that sICAM-1 mRNA expression in response to TNFa
occurs at a higher concentration (100-fold) than that of mI-
CAM-1. However, it is possible to detect, in the extracellular
milieu, a signiﬁcant elevation of sICAM-1 after treatment0
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305Osteoarthritis and Cartilage Vol. 15, No. 3with TNFa at a much lower concentration. This could simply
reﬂect increased cleavage of already present mICAM-1 that
is initiated at low TNFa concentration. However, if this were
true, sICAM-1 levels would remain high with combined incu-
bation of TNFa and ActD. Furthermore, in contrast to mI-
CAM-1, sICAM-1 levels are not inﬂuenced by protein
kinase inhibitors. Taken together, these results suggest
that there are two separate pathways for the generation
and regulation of mICAM-1 expression and sICAM-1 pro-
duction in human OA osteoblasts.
Our data seem to be in accordance with those of Wakat-
suki et al.23 who reported a speciﬁc mRNA coding for sI-
CAM-1. We observed the presence of sICAM-1 mRNA
splice in human osteoblasts using the speciﬁc primers of
Wakatsuki et al.23. The meaning of this ﬁnding in bone re-
mains to be deﬁned. However, in various inﬂammatory
and malignant pathological conditions, increased expres-
sion of sICAM-1 indicates a possible reciprocal relationship
between sICAM-1 and inﬂammation18,19. However, the rela-
tionship between circulating and membrane-bound ICAM-1
is controversial. Some studies report a similar physiological
role for these two molecules, whereas others describe op-
posite actions22,37e41. We can only postulate whether sI-
CAM-1 inhibits cellular adhesion or promotes the effect of
mICAM-1 in bone metabolism. An anti-osteoclastogenic
role for sICAM-1 would place it in the same category as os-
teoprotegerin (OPG), while a pro-osteoclastogenic role
would potentially act in the same manner as soluble recep-
tor activator of nuclear factor-kappaB ligand (sRANKL). Al-
though the exact role of sICAM-1 remains elusive, we
believe that increased mICAM-1 expression in response
to TNFa stimulation could facilitate the interaction of osteo-
blasts with osteoclast precursors.
TNFa, a pleiotropic cytokine primarily produced by acti-
vated macrophages and T-lymphocytes, has a wide range
of biological effects, including inﬂammation, mitogenesis,
differentiation, immune modulation and anti-tumor immu-
nity42. TNFa is also considered to be one of most important
cytokines implicated in osteoporosis, arthritis and wear de-
bris-induced osteolysis28. It supports the differentiation and
survival of osteoclasts, but not resorption activity. The ability
of osteoblasts to express adhesion molecules, such as
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Fig. 4. Time course of the effect of TNFa on cell signaling path-
ways. Human OA osteoblasts were treated with 10 ng/ml TNFa
for the indicated times. Total cell lysates (approximately 20 mg)
were prepared and subjected to Western blot analysis with the
phosphospeciﬁc antibodies anti-phospho-p38 MAPK (n¼ 3), anti-
phospho-p44/42 MAPK (n ¼ 3), anti-phospho-p54/46 MAPK
(n¼ 3), or anti-phospho-IkBa (n¼ 3).A
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Fig. 5. Effect of protein kinase inhibitors and NF-kB inhibitor on
TNFa-induced ICAM-1. The cells were pre-incubated for 30 min
with different chemical inhibitors: (A) SB202190 (a p38 MAPK inhib-
itor), (B) PD98059 (a p44/42 MAPK inhibitor), and (C) PDTC (a NF-
kB inhibitor), followed by another incubation for 24 h in the presence
or absence of 10 ng/ml TNFa. Values are expressed as % of TNFa-
treated osteoblasts (n¼ 4). Statistical analysis was performed by
Student’s t test. P values are compared to the corresponding value
for cells incubated in the absence of TNFa. *P< 0.05, **P< 0.01.
306 Q. Shi et al.: ICAM-1 expression in human osteoblastsICAM-1, in addition to their ability to produce and respond to
different cytokines, such as TNFa, IL-1b, IFN-g, transform-
ing growth factor-beta (TGFb), and IL-6, suggests that oste-
oblasts can function as modulators and/or effectors of
inﬂammatory processes and osteoclastogenesis. We be-
lieve that the osteoclastogenic action of these cytokines
is, at least in part, modulated through ICAM-1.
Our results disclosed that the induction of ICAM-1 ex-
pression could be prevented by co-incubation with ActD
(an inhibitor of RNA transcription). This means that the
induction of ICAM-1 expression requires de novo mRNA
synthesis, indicating its regulation at the transcriptional
level. Investigations into the signal transduction pathways
of TNFa showed rapid and signiﬁcant phosphorylation of
p38, p44/42, p54/46 MAPK as well as IkBa. Next, we tested
the effects of MAPK- and NF-kB-speciﬁc inhibitors on
TNFa-induced mICAM-1. Our data revealed that all chemi-
cal inhibitors, SB202190, PD98059 and PDTC, abrogated
TNFa-induced mICAM-1 protein expression. Interestingly,
these chemical products failed to inhibit sICAM-1 upregula-
tion by TNFa. Furthermore, the overexpression of WT p38
MAPK and IKKa enhanced TNFa-induced mICAM-1. These
results were supported by other recent studies indicating
that TNFa is a potent inducer of ICAM-1 in various cell
types43,44. It has been reported that the activation of p38
MAPK and NF-kB appears necessary for the regulation of
ICAM-1 expression. In the ICAM-1 promoter, numerous
cis-elements have been identiﬁed to exert transcriptional
control of ICAM-1. Among these elements, NF-kB and acti-
vator protein 1 (AP-1) were shown to act as the most critical
of these regulatory elements for ICAM-1 transcription45.
Mutation in the AP-1 and NF-kB sequence attenuates
pro-inﬂammatory cytokine-stimulated ICAM-1 promoter
activity46,47. While increased sICAM-1 levels can be attrib-
uted to its transcriptional regulation, another mechanism
has been considered crucial in sICAM-1. This mechanism
includes the proteolytic cleavage of mICAM-1 by MMPs.
To investigate it, osteoblasts were co-treated with 10 nM
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Fig. 6. Effect of IKKa and p38 MAPK overexpression on TNFa-in-
duced mICAM-1 expression. Transient transfection of MG-63 oste-
oblasts was performed with 1 mg of expression vectors of either
IKKa, WT or DN p38 MAPK, as described in Materials and
methods. Six hours after transfection, fresh 0.5% FBS/DMEM
was added in the absence or presence of 10 ng/ml TNFa for an-
other 24 h. After incubation, the cells were ﬁxed, and mICAM-1
levels were quantiﬁed by ELISA. Values are the means S.E.M. of
three experiments. Statistical analysis was performed by Student’s
t test. P values are compared to the corresponding value for cells
incubated in the absence of TNFa. *P< 0.05, **P< 0.01.of an inhibitor of MMP-9 and 10 ng/ml TNFa. We observed
that the addition of MMP-9 inhibitor I signiﬁcantly reduced
TNFa-enhanced sICAM-1 expression, which was consis-
tent with other reports20,48. Other inhibitors of MMP-9,
such as Batimastat, have been shown to inhibit TNFa-
induced mICAM-1 cleavage in primary glial cells. Further
experiments using a speciﬁc antibody for splice variant-
derived sICAM-1 (relative to conventional cell surface
ICAM-1) will be performed to investigate the relationship
between ICAM-1 and MMP-9.
Conclusion
This study reports an increase in ICAM-1 expression after
the exposure of human osteoblasts to TNFa . This height-
ened expression appears to be mediated through activation
of MAPK and IKKa cascades. Further, the regulation of sI-
CAM-1 includes two mechanisms: (1) shedding/cleavage of
conventional cell surface ICAM-1 protein by MMP-9, and (2)
de novo synthesis from a speciﬁc coding mRNA. It is well-
known that ICAM-1 has a close relationship with inﬂamma-
tion, and TNFa has many effects in producing inﬂammatory
responses. Therapeutic approaches have been taken to in-
duce anti-inﬂammatory effects by blocking the ICAM-1 or
TNFa-dependent pathway with a neutralizing antibody49.
In bone disease, blockage of the interaction between
TNFa and ICAM-1 may inhibit not only inﬂammation in
the joint but also bone resorption by suppressing the
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Fig. 7. Role of MMP-9-mediating sICAM-1 release. (A) Osteoblasts
were pre-incubated for 1 h in the absence or presence of MMP-9
inhibitor (10 nM), followed by incubation with or without TNFa
(10 ng/ml) for another 24 h. Then, sICAM-1 expression was evalu-
ated by ELISA. (B) Osteoblasts were treated with increasing con-
centrations of TNFa (0.1e10 ng/ml) for 24 h, and the culture
medium was collected for Western blotting, using rabbit anti-
MMP-9 antibody. Values are the means S.E.M. of three experi-
ments. Statistical analysis was performed by Student’s t test.
P values represent control vs MMP-9 inhibitor, control vs TNFa,
control vs TNFaþMMP-9 inhibitor, and TNFa vs TNFaþMMP-9
inhibitor. *P< 0.05, **P< 0.01.
307Osteoarthritis and Cartilage Vol. 15, No. 3osteoblast-mediated formation of osteoclasts49. These ﬁnd-
ings could have clinical implications in the future treatment
of bone loss diseases, such as osteoporosis, arthritis and
aseptic loosening.
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